[1]
|
朱呈光, 贺湘玲, 汤止戈, 等. 44例儿童神经母细胞瘤临床分析[J]. 中国当代儿科杂志, 2020, 22(11): 1193-1197.
|
[2]
|
Chung, C., Boterberg, T., Lucas, J., et al. (2021) Neuroblastoma. Pediatr Blood Cancer, 68, e28473.
https://doi.org/10.1002/pbc.28473
|
[3]
|
Brodeur, G.M. (2003) Neuroblastoma: Biological Insights into a Clinical Enigma. Nature Reviews Cancer, 3, 203-216.
https://doi.org/10.1038/nrc1014
|
[4]
|
Matthay, K.K., Maris, J.M., Schleiermacher, G., et al. (2016) Neuroblastoma. Nature Reviews Disease Primers, 2, 16078.
https://doi.org/10.1038/nrdp.2016.78
|
[5]
|
鲁冬芳, 陈希, 舒强. 高危神经母细胞瘤分子遗传学特征研究进展[J]. 中华小儿外科杂志, 2021, 42(1): 81-7.
|
[6]
|
韩森, 马旭, 方健. 端粒与端粒酶研究在肺癌中的临床应用前景与挑战[J]. 中国肺癌杂志, 2021, 24(1): 25-30.
|
[7]
|
Shay, J.W. and Wright, W.E. (2019) Telomeres and Telomerase: Three Decades of Progress. Nature Reviews Genetics, 20, 299-309. https://doi.org/10.1038/s41576-019-0099-1
|
[8]
|
Robinson, N.J. and Schiemann, W.P. (2022) Telomerase in Can-cer: Function, Regulation, and Clinical Translation. Cancers (Basel), 14, 201. https://doi.org/10.3390/cancers14030808
|
[9]
|
Dogan, F. and Forsyth, N.R. (2021) Telomerase Regulation: A Role for Epigenetics. Cancers (Basel), 13, 1213.
https://doi.org/10.3390/cancers13061213
|
[10]
|
Kim, N.W., Piatyszek, M.A., Prowse, K.R., et al. (1994) Specific Association of Human Telomerase Activity with Immortal Cells and Cancer. Science, 266, 2011-2015. https://doi.org/10.1126/science.7605428
|
[11]
|
Bejarano, L., Bosso, G., Louzame, J., et al. (2019) Multiple Cancer Pathways Regulate Telomere Protection. EMBO Molecular Medicine, 11, e10292. https://doi.org/10.15252/emmm.201910292
|
[12]
|
Varela, E. and Blasco, M.A. (2009) Nobel Prize in Physiology or Medicine: Telomeres and Telomerase. Oncogene, 29, 1561-1565. https://doi.org/10.1038/onc.2010.15
|
[13]
|
Smith, L., Luchini, C., Demurtas, J., et al. (2019) Telomere Length and Health Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies. Ageing Research Reviews, 51, 1-10.
https://doi.org/10.1016/j.arr.2019.02.003
|
[14]
|
Hägg, S., Zhan, Y., Karlsson, R., et al. (2017) Short Telomere Length Is Associated with Impaired Cognitive Performance in European Ancestry Cohorts. Translational Psychiatry, 7, e1100. https://doi.org/10.1038/tp.2017.73
|
[15]
|
Haycock, P.C., Burgess, S., Nounu, A., et al. (2017) Association between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. JAMA Oncology, 3, 636-651.
https://doi.org/10.1001/jamaoncol.2016.5945
|
[16]
|
Zachek, C.M., Miller, M.D., Hsu, C., et al. (2015) Children’s Cancer and Environmental Exposures: Professional Attitudes and Practices. Journal of Pediatric Hematology/Oncology, 37, 491-497.
https://doi.org/10.1097/MPH.0000000000000416
|
[17]
|
Ackermann, S., Cartolano, M., Hero, B., et al. (2018) A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma. Science, 362, 1165-1170. https://doi.org/10.1126/science.aat6768
|
[18]
|
Dagg, R.A., Pickett, H.A., Neumann, A.A., et al. (2017) Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. Cell Reports, 19, 2544-2556. https://doi.org/10.1016/j.celrep.2017.05.087
|
[19]
|
Lin, S.Y. and Elledge, S.J. (2003) Multiple Tumor Suppressor Pathways Negatively Regulate Telomerase. Cell, 113, 881-889. https://doi.org/10.1016/S0092-8674(03)00430-6
|
[20]
|
Bell, R.J., Rube, H.T., Xavier-Magalhães, A., et al. (2016) Understanding TERT Promoter Mutations: A Common Path to Immortality. Molecular Cancer Research, 14, 315-323. https://doi.org/10.1158/1541-7786.MCR-16-0003
|
[21]
|
Brady, S.W., Liu, Y., Ma, X., et al. (2020) Pan-Neuroblastoma Analysis Reveals Age- and Signature-Associated Driver Alterations. Nature Communications, 11, 5183. https://doi.org/10.1038/s41467-020-18987-4
|
[22]
|
Kang, J.U., Koo, S.H., Kwon, K.C., et al. (2008) Gain at Chromosomal Region 5p15.33, Containing TERT, Is the Most Frequent Genetic Event in Early Stages of Non-Small Cell Lung Cancer. Cancer Genetics and Cytogenetics, 182, 1-11. https://doi.org/10.1016/j.cancergencyto.2007.12.004
|
[23]
|
Peifer, M., Hertwig, F., Roels, F., et al. (2015) Telomer-ase Activation by Genomic Rearrangements in High-Risk Neuroblastoma. Nature, 526, 700-704. https://doi.org/10.1038/nature14980
|
[24]
|
Martínez, P. and Blasco, M.A. (2011) Telomeric and Extra-Telomeric Roles for Telomerase and the Telomere-Binding Proteins. Nature Reviews Cancer, 11, 161-176. https://doi.org/10.1038/nrc3025
|
[25]
|
Saretzki, G. (2014) Extra-Telomeric Functions of Human Telomerase: Cancer, Mitochondria and Oxidative Stress. Current Pharmaceutical Design, 20, 6386-6403. https://doi.org/10.2174/1381612820666140630095606
|
[26]
|
Koh, C.M., Khattar, E., Leow, S.C., et al. (2015) Te-lomerase Regulates MYC-Driven Oncogenesis Independent of Its Reverse Transcriptase Activity. Journal of Clinical Investigation, 125, 2109-2122. https://doi.org/10.1172/JCI79134
|
[27]
|
Park, J.I., Venteicher, A.S., Hong, J.Y., et al. (2009) Telomerase Modulates Wnt Signalling by Association with Target Gene Chromatin. Nature, 460, 66-72. https://doi.org/10.1038/nature08137
|
[28]
|
Ghosh, A., Saginc, G., Leow, S.C., et al. (2012) Telomerase Directly Regulates NF-κB-Dependent Transcription. Nature Cell Biology, 14, 1270-1281. https://doi.org/10.1038/ncb2621
|
[29]
|
Khattar, E. and Tergaonkar, V. (2017) Transcriptional Regulation of Te-lomerase Reverse Transcriptase (TERT) by MYC. Frontiers in Cell and Developmental Biology, 5, 1. https://doi.org/10.3389/fcell.2017.00001
|
[30]
|
Schaub, F.X., Dhankani, V., Berger, A.C., et al. (2018) Pan-Cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems, 6, 282-300.e2.
|
[31]
|
Yu, E.Y., Cheung, N.V. and Lue, N.F. (2022) Connecting Telomere Maintenance and Regulation to the Developmental Origin and Differentiation States of Neuroblastoma Tumor Cells. Journal of Hematology & Oncology, 15, 117.
https://doi.org/10.1186/s13045-022-01337-w
|
[32]
|
Hartlieb, S.A., Sieverling, L., Nadler-Holly, M., et al. (2021) Alternative Lengthening of Telomeres in Childhood Neuroblastoma from Genome to Proteome. Nature Communications, 12, 1269.
https://doi.org/10.1038/s41467-021-21247-8
|
[33]
|
Meeser, A., Bartenhagen, C., Werr, L., et al. (2022) Reliable Assessment of Telomere Maintenance Mechanisms in Neuroblastoma. Cell & Bioscience, 12, 160. https://doi.org/10.1186/s13578-022-00896-2
|
[34]
|
Zeineldin, M., Federico, S., Chen, X., et al. (2020) MYCN Am-plification and ATRX Mutations Are Incompatible in Neuroblastoma. Nature Communications, 11, 913. https://doi.org/10.1038/s41467-020-14682-6
|
[35]
|
Nakagawara, A., Li, Y., Izumi, H., et al. (2018) Neuroblastoma. Japanese Journal of Clinical Oncology, 48, 214-241.
https://doi.org/10.1093/jjco/hyx176
|
[36]
|
Ackermann, S. and Fischer, M. (2019) Telomere Maintenance in Pediatric Cancer. International Journal of Molecular Sciences, 20, 5836. https://doi.org/10.3390/ijms20235836
|
[37]
|
Koneru, B., Lopez, G., Farooqi, A., et al. (2020) Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. Cancer Research, 80, 2663-2675. https://doi.org/10.1158/0008-5472.CAN-19-3068
|
[38]
|
Cheung, N.K., Zhang, J., Lu, C., et al. (2012) Association of Age at Diagnosis and Genetic Mutations in Patients with Neuro-blastoma. JAMA, 307, 1062-1071. https://doi.org/10.1001/jama.2012.228
|
[39]
|
Yu, E.Y., Cheung, I.Y., Feng, Y., et al. (2019) Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma. Neoplasia, 21, 689-701. https://doi.org/10.1016/j.neo.2019.04.002
|
[40]
|
Rivera, T., Haggblom, C., Cosconati, S., et al. (2017) A Balance between Elongation and Trimming Regulates Telomere Stability in Stem Cells. Nature Structural & Molecular Biology, 24, 30-39. https://doi.org/10.1038/nsmb.3335
|
[41]
|
Moreno, L., Barone, G., Dubois, S.G., et al. (2020) Accelerat-ing Drug Development for Neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblas-toma. European Journal of Cancer, 136, 52-68.
https://doi.org/10.1016/j.ejca.2020.05.010
|
[42]
|
Roderwieser, A., Sand, F., Walter, E., et al. (2019) Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma. JCO Precision Oncology, 3, 1-20. https://doi.org/10.1200/PO.19.00072
|
[43]
|
Gomez, D.L., Armando, R.G., Cerrudo, C.S., et al. (2016) Telomerase as a Cancer Target. Development of New Molecules. Current Topics in Medicinal Chemistry, 16, 2432-2440. https://doi.org/10.2174/1568026616666160212122425
|
[44]
|
Wade, M., Fox, N.A., Zeanah, C.H., et al. (2020) Te-lomere Length and Psychopathology: Specificity and Direction of Effects within the Bucharest Early Intervention Project. Journal of the American Academy of Child & Adolescent Psychiatry, 59, 140-148.e3. https://doi.org/10.1016/j.jaac.2019.02.013
|